Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
3.100
-0.030 (-0.96%)
Aug 14, 2025, 1:59 PM - Market open

Alto Neuroscience Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-64.86-61.43-36.31-27.71-9.19
Depreciation & Amortization
0.630.50.370.340.15
Loss (Gain) From Sale of Assets
0.080.050.14--
Asset Writedown & Restructuring Costs
0.740.74---
Stock-Based Compensation
7.547.632.891.760.23
Other Operating Activities
1.281.030.150.630.13
Change in Accounts Receivable
---1.16-1.29
Change in Accounts Payable
-0.30.52-0.631.010.46
Change in Other Net Operating Assets
-0.183.54-0.072.420.26
Operating Cash Flow
-55.08-47.42-33.45-20.39-9.26
Capital Expenditures
-1.54-2.08-0.47-0.73-0.68
Investing Cash Flow
-1.54-2.08-0.47-0.73-0.68
Long-Term Debt Issued
-1.25-9.83-
Net Debt Issued (Repaid)
10.731.25-9.83-
Issuance of Common Stock
0.31137.770.180.040.01
Other Financing Activities
0.07-3.33-2.05-0.34-0.21
Financing Cash Flow
11.11135.6968.1343.7931.69
Foreign Exchange Rate Adjustments
-0.03-0.01-0.01-0.02-0.05
Net Cash Flow
-45.5486.1834.222.6421.7
Free Cash Flow
-56.62-49.5-33.92-21.13-9.94
Free Cash Flow Margin
-----4734.29%
Free Cash Flow Per Share
-2.10-2.01-9.09-6.13-4.12
Cash Interest Paid
110.91--
Levered Free Cash Flow
-37.4-32.29-23.45-12.3-
Unlevered Free Cash Flow
-36.54-31.44-22.6-12.3-
Change in Working Capital
-0.484.06-0.74.58-0.57
Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q